The study showed a mean reduction in HbA1c of 0.86% at 3 months, 1.27% at 6 months, and 1.67% at 12 months for patients with T2D on oral antidiabetics and a mean reduction of 0.94%, 1.33%, and 1.73% at 3, 6, and 12 months, respectively, for patients with T2D on basal insulin and oral antidiabetics after starting CGM (42). This evidence concerns the gene INS and type 2 diabetes mellitus.